Focal cerebral ischemia in the TNFalpha-transgenic rat by Pettigrew, L. Creed et al.
University of Kentucky
UKnowledge
Sanders-Brown Center on Aging Faculty
Publications Aging
10-23-2008
Focal cerebral ischemia in the TNFalpha-transgenic
rat
L. Creed Pettigrew
University of Kentucky, cpetti@uky.edu
Mark S. Kindy
Medical University of South Carolina
Stephen W. Scheff
University of Kentucky, sscheff@email.uky.edu
Joe E. Springer
University of Kentucky, joe.springer@uky.edu
Richard J. Kryscio
University of Kentucky, kryscio@email.uky.edu
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/sbcoa_facpub
Part of the Family, Life Course, and Society Commons, and the Geriatrics Commons
This Article is brought to you for free and open access by the Aging at UKnowledge. It has been accepted for inclusion in Sanders-Brown Center on
Aging Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Pettigrew, L. Creed; Kindy, Mark S.; Scheff, Stephen W.; Springer, Joe E.; Kryscio, Richard J.; Li, Yizhao; and Grass, David S., "Focal
cerebral ischemia in the TNFalpha-transgenic rat" (2008). Sanders-Brown Center on Aging Faculty Publications. 25.
https://uknowledge.uky.edu/sbcoa_facpub/25
Authors
L. Creed Pettigrew, Mark S. Kindy, Stephen W. Scheff, Joe E. Springer, Richard J. Kryscio, Yizhao Li, and
David S. Grass
Focal cerebral ischemia in the TNFalpha-transgenic rat
Notes/Citation Information
Published in Journal of Neuroinflammation, v. 5, 47.
© 2008 Pettigrew et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Digital Object Identifier (DOI)
http://dx.doi.org/10.1186/1742-2094-5-47
This article is available at UKnowledge: https://uknowledge.uky.edu/sbcoa_facpub/25
BioMed Central
Page 1 of 19
(page number not for citation purposes)
Journal of Neuroinflammation
Open AccessResearch
Focal cerebral ischemia in the TNFalpha-transgenic rat
L Creed Pettigrew*1,2,3, Mark S Kindy4,5, Stephen Scheff1, Joe E Springer6, 
Richard J Kryscio7, Yizhao Li8 and David S Grass9
Address: 1Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA, 2Department of Neurology, University of Kentucky, 
Lexington, Kentucky, USA, 3Veterans Administration (VA) Medical Center, Lexington, Kentucky, USA, 4Department of Neuroscience, Medical 
University of South Carolina, Charleston, South Carolina, USA, 5Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA, 
6Department of Physical Medicine & Rehabilitation, University of Kentucky, Lexington, Kentucky, USA, 7Department of Statistics and School of 
Public Health, University of Kentucky, Lexington, Kentucky, USA, 8Jinan Great Wall Hospital, Jinan, Shandong, PR China and 9Xenogen 
Biosciences, Cranbury, New Jersey, USA
Email: L Creed Pettigrew* - cpetti@uky.edu; Mark S Kindy - kindyms@musc.edu; Stephen Scheff - sscheff@email.uky.edu; 
Joe E Springer - joe.springer@uky.edu; Richard J Kryscio - kryscio@email.uky.edu; Yizhao Li - swillia@uky.edu; 
David S Grass - David.Grass@xenogen.com
* Corresponding author    
Abstract
Background: To determine if chronic elevation of the inflammatory cytokine, tumor necrosis
factor-α (TNFα), will affect infarct volume or cortical perfusion after focal cerebral ischemia.
Methods: Transgenic (TNFα-Tg) rats overexpressing the murine TNFα gene in brain were
prepared by injection of mouse DNA into rat oocytes. Brain levels of TNFα mRNA and protein
were measured and compared between TNFα-Tg and non-transgenic (non-Tg) littermates. Mean
infarct volume was calculated 24 hours or 7 days after one hour of reversible middle cerebral artery
occlusion (MCAO). Cortical perfusion was monitored by laser-Doppler flowmetry (LDF) during
MCAO. Cortical vascular density was quantified by stereology. Post-ischemic cell death was
assessed by immunohistochemistry and regional measurement of caspase-3 activity or DNA
fragmentation. Unpaired t tests or analysis of variance with post hoc tests were used for
comparison of group means.
Results: In TNFα-Tg rat brain, the aggregate mouse and rat TNFα mRNA level was fourfold higher
than in non-Tg littermates and the corresponding TNFα protein level was increased fivefold (p ≤
0.01). Infarct volume was greater in TNFα-Tg rats than in non-Tg controls at 24 hours (p ≤ 0.05)
and 7 days (p ≤ 0.01). Within the first 10 minutes of MCAO, cortical perfusion measured by LDF
was reduced in TNFα-Tg rats (p ≤ 0.05). However, regional vascular density was equivalent
between TNFα-Tg and non-Tg animals (p = NS). Neural cellular apoptosis was increased in
transgenic animals as shown by elevated caspase-3 activity (p ≤ 0.05) and DNA fragmentation (p ≤
0.001) at 24 hours.
Conclusion: Chronic elevation of TNFα protein in brain increases susceptibility to ischemic injury
but has no effect on vascular density. TNFα-Tg animals are more susceptible to apoptotic cell death
after MCAO than are non-Tg animals. We conclude that the TNFα-Tg rat is a valuable new tool
for the study of cytokine-mediated ischemic brain injury.
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Background
Tumor necrosis factor-α (TNFα) is a pleiotropic cytokine
suspected to enhance or deter cellular survival through
activation of receptor-mediated signal transduction.
When present in supra-physiological levels after injury, it
is known to modulate neural cell loss in cerebral ischemia
[1], intracerebral hemorrhage [2], chronic cerebral
oligemia [3], and trauma [4]. The level of TNFα in human
brain becomes elevated after cerebral infarction [5] and
appears sequentially in the infarct core and peri-infarct
areas before expression in tissue within the unaffected
hemisphere [6]. Elevated levels of TNFα have been
observed consistently in serum [7-9] and in cerebrospinal
fluid [8,9] after acute ischemic stroke. In animal models of
cerebral ischemia, high levels of TNFα have been found
after global [10,11] and focal [12] ischemic injury. Several
investigators reported reduction of infarct volume
through inhibition of TNFα [13-15], although Nawashiro
and colleagues [16] showed that pretreatment of mice by
intracisternal administration of TNFα reduced infarct vol-
ume paradoxically without an inhibitor.
Active, soluble TNFα is derived through proteolytic cleav-
age from a transmembrane precursor by TNF convertase
(TACE), a member of the disintegrin and metalloprotein-
ase (ADAM) group of enzymes. Among neural cell types,
soluble TNF is secreted robustly by microglia and astro-
cytes [17,18] but is also expressed by neurons and steroid-
producing cells of the adrenal zona reticularis. Once
released, soluble TNF circulates as a homotrimer that will
bind with one of two distinct receptors of 55-kDa
(TNFR1) or 75-kDa (TNFR2) molecular weight. The com-
plex interactions of both soluble and transmembrane
TNFα with the two TNF receptors have been reviewed
[19]. The first receptor, p55/TNFR1, may bind either form
of TNFα before dissociating from an endogenous inhibi-
tor and recruiting the TNF receptor-associated protein
death domain (TRADD). Once complexed, p55/TNFR1-
TRADD may either facilitate apoptosis by activation of
caspase-8 or enhance cell survival through disinhibition
of the nuclear transcription factor, NFκB. The second
receptor, p75/TNFR2, becomes active only upon binding
transmembrane TNFα and will develop a low-affinity
interaction with TRADD. The p75/TNFR2-TRADD con-
struct is less stable than p55/TNFR1-TRADD and is con-
sidered to have a more focused role in cell survival by
upregulating anti-apoptotic factors or preventing activa-
tion of caspase-8. Certain steps in the cascade, such as the
activation of caspase-8 to induce apoptosis and the release
of NFκB to generate pro-survival elements, arise upon
stimulation of the same receptor (p55/TNFR1) and may
constitute a natural check-and-balance system that deter-
mines the ultimate fate of the cell.
Our previous work suggests that the apparent duality of
effect attributed to TNFα is controlled by interaction
between the cytokine ligand and p55/TNFR1 or p75/
TNFR2. We demonstrated that inactivation of both recep-
tors in double-knockout mice causes exacerbation of the
excitotoxic effects of kainic acid in the CA3 region of the
hippocampus and expansion of infarct volume after mid-
dle cerebral artery occlusion (MCAO) [20]. We further
highlighted the role of p55/TNFR1 as a gatekeeper mole-
cule by showing that knock-out mice lacking only this
receptor had significantly greater neuronal injury after kai-
nic acid injection or MCAO [21].
In this paper, we describe the first application of focal cer-
ebral ischemia in a unique transgenic rat overexpressing
the murine TNFα gene. We present the results of a feasibil-
ity experiment testing the hypothesis that chronic eleva-
tion of TNFα in brain increases infarct volume after focal
cerebral ischemia. We also report on comparison of
TNFα-transgenic (TNFα-Tg) rats with non-transgenic
(non-Tg) controls to determine if overexpression of the
TNFα gene alters the vascular anatomy of the cerebral cor-
tex, the circulatory response of the brain to ischemia, or
post-ischemic cellular apoptosis. Our overall goal in per-
forming this work was to determine how elevated levels of
TNFα protein, such as may be observed in human brain
after stroke, will modify cerebral ischemic injury.
Methods
Construction of the transgenic animal
The TNFα-Tg rat was constructed in the research facility of
Xenogen Biosciences in Cranbury, New Jersey. Construc-
tion began by isolation of the murine TNFα gene from a
129 SV mouse genomic library as described previously
[22]. The 2.8 kb EcoRI fragment containing the murine
TNFα promoter and the entire coding region of the corre-
sponding murine TNFα gene was ligated to the 0.77 kb
EcoRI-PstI/SalI fragment containing the 3'-untranslated
region and polyadenylation signal of the human β-globin
gene [23]. The BamHI-SalI fragment was microinjected
into fertilized eggs of Sprague-Dawley (S-D) rats using
standard techniques [24]. TNFα-Tg males were bred to
female, wild type S-D rats. Approximately half of the
resulting offspring carried the murine TNFα gene, as con-
firmed by polymerase chain reaction (PCR) genotyping
with primers specific for the murine TNFα gene, 5'-GGG
GAA AGG TGG TAT CTC-3' (sense primer) and 5'-CGC
TTT CTT GCT GTC CAA-3' (antisense primer) applied to
total cellular DNA isolated from tail snip tissue.
Measurement of TNFα mRNA and protein
The Institutional Animal Care and Use Committee of the
University of Kentucky approved all experiments per-
formed with the TNFα-Tg rat. To analyze TNFα mRNA lev-
els in TNFα-Tg and non-Tg brain, reverse transcriptase-
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PCR (RT-PCR; Ambion, Austin, TX) was performed on
total RNA isolated from one cerebral hemisphere. An
enzyme-linked immunosorbent assay (ELISA) was used to
detect aggregate mouse and rat TNFα in the remaining cer-
ebral hemisphere (R & D Systems, Minneapolis, MN).
To determine the contribution of the native rat gene to the
mRNA response, we screened for rat TNFα mRNA in dif-
ferent brain regions, external organs, and serum in a sec-
ond set of animals. Samples were homogenized and total
RNA was extracted with an RNeasy Mini Kit (QIAGEN
Inc., Valencia, CA). The Quantikine rat TNFα probes and
Calibrator Kit (#RN510) was then used with an mRNA
base kit (#RN000) of R & D Systems to quantify rat TNFα
mRNA. Parallel samples were homogenized in phos-
phate-buffered saline (PBS), centrifuged, and total rat and
mouse TNFα was measured by ELISA (R & D Systems;
Quantikine M catalog #MTA00).
To measure TNFα protein and mouse or rat mRNA in
small quantities of brain tissue (= 50 mg) obtained from
ischemic animals, we developed a micro-sample prepara-
tion technique and refined our protein ELISA and mRNA
quantification methods. Tissue samples obtained from
the border zone approximating the ischemic penumbra
and the infarct core in the rat brain were homogenized in
Mammalian Tissue Lysis Buffer (#C3228; Sigma Chemical
Company, St. Louis, MO) consisting of a dialyzable mild
detergent (bicine), 150 mM NaCl, and a cocktail of pro-
tease inhibitors (Roche). The homogenates were centri-
fuged at 12,000 × g for 10 minutes at 4°C. Protein
concentration was quantified with the BCA protein assay
kit (#23225, Pierce Chemicals, Rockford, IL).
For measurement of TNFα protein in small tissue sam-
ples, we used an ELISA kit (eBioscience, San Diego, CA)
containing a monoclonal antibody that can detect both
mouse and rat TNFα protein in the range of 10 pg/ml – 10
ng/ml. To measure rat or mouse mRNA in small tissue
samples, we extracted total RNA with the RNeasy Mini Kit
and used the same Quantikine mRNA base kit described
above. Quantikine rat TNFα mRNA probes and Calibrator
Kit (#RN510) and Quantikine mouse TNFα mRNA
probes and Calibrator Kit (#RN410) with Quantikine
mRNA base kit (#RN000) of R & D Systems were used to
quantify mouse and rat TNFα mRNA. After completion of
this assay, mouse or rat TNFα mRNA was quantified in
attomoles/ml/1 μg total RNA and expressed as a ratio
(mouse/rat TNFα mRNA).
Western blot analysis for TRADD protein
We measured expression of TRADD protein, derived upon
interaction of active, soluble TNFα with p55/TNFR1, to
demonstrate that TNFα protein retained biological activ-
ity in the ischemic brain of the TNFα-Tg rat. Micro-sam-
ples of brain tissue were homogenized and prepared as
described for measurement of TNFα protein. The expres-
sion of TRADD protein was determined by western blot
analysis using a monoclonal anti-TRADD antibody (BD
Biosciences, USA). Aliquots of brain homogenate (30 μg
of protein) were loaded onto 10% SDS-PAGE gels for elec-
trotransfer onto nitrocellulose membranes. After transfer,
the membranes were blocked by incubation in 5% BSA in
TRIS-buffered saline with 0.01% Tween-20 for one hour at
room temperature and were washed three times (10 min-
utes each) with wash buffer (1 × TBS, 0.05% Tween-20).
The membranes were then incubated with primary anti-
body (anti-TRADD monoclonal antibody; #610572, BD
Biosciences Pharmingen, San Diego, CA) at a dilution of
1:250 for one hour at room temperature. The nitrocellu-
lose membrane was then washed and incubated with
horseradish peroxidase-conjugated goat anti-mouse IgG
(1:1,000; #34080, Cell Signaling Technology, Danvers,
MA) for another hour at room temperature. After three
additional washes in TBS/Tween-20, immunoreactive
bands were developed using an ECL chemiluminescence
substrate (#34080, Pierce). A densitometry image analysis
system (Kodak 2000RT) was used for quantification of
band intensities on X-ray film. To screen for gel loading
errors, the western blots were stripped and reprobed with
an antibody to β-actin, a constitutively expressed protein.
Immunohistochemical studies
For immunohistochemical studies confirming cell iden-
tity and intracellular expression of TNFα, we prepared 30-
μm coronal brain slices and applied methods described in
our previous publications [25-27]. We used a rabbit poly-
clonal antibody to identify both rat and mouse TNFα
(AMC3012, Biosource International, Camarillo, CA;
1:2000 dilution). We chose NeuN (MAB377, Chemicon
International, Temecula, CA; mouse monoclonal; 1:1000
dilution) to immunolabel neuronal nuclear protein, anti-
GFAP (anti-glial fibrillary acidic protein; MAB3402,
Chemicon; mouse monoclonal; 1:1000 dilution) to iden-
tify astroglia, CD11b/OX-42 (MAB1405, Chemicon;
mouse monoclonal; 1:1000 dilution) to label microglia
and macrophages, and anti-APC/Ab-7 (anti-oligodendro-
glial cell body; OP80, Oncogene Research Products;
mouse monoclonal; 1:1000 dilution) to identify oli-
godendrocytes. To identify what type of neural cell was
expressing TNFα in the transgenic animal, co-localization
studies were performed by incubating coronal brain sec-
tions with the anti-TNFα antibody and NeuN, anti-GFAP,
CD11b/OX-42, or anti-APC/Ab-7 labeled with fluoro-
phores.
Suture-occlusion model of focal cerebral ischemia
Because the murine TNFα gene was expressed within S-D
rats, we chose the Zea Longa technique [28] for suture-
occlusion of the MCA already validated in this animal
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strain. Male transgenic and non-Tg rats of 250–350 gm
body weight were subjected to one hour of suture-occlu-
sion by our modification [29] of the original Zea Longa
method. Each animal was fasted overnight in preparation
for surgery and then anesthetized by IP injection of chlo-
ral hydrate (350 mg/kg) and xylazine (4 mg/kg). Rectal
and temporalis muscle temperatures were maintained at
36.5–37.5°C by external warming. A suture-occluder pre-
pared by the method of Belayev and others [30] was
advanced retrograde through the external carotid artery
and into the internal carotid artery to occlude the MCA.
After one hour, the suture-occluder was withdrawn. In
each rat, the left femoral artery was reversibly cannulated
for assessment of mean arterial blood pressure (MABP)
and blood gases before, during, and after suture-occlu-
sion.
Measurement of infarct volume
Infarct volume was measured 24 hours or 7 days after
removal of the suture-occluder from the MCA in ischemic
animals. Rats prepared for measurement of infarct volume
were re-anesthetized by IP injection of the same com-
bined doses of chloral hydrate and xylazine used as
anesthesia for surgery to achieve focal cerebral ischemia.
For brain sampled after 24 hours of post-ischemic reper-
fusion, each anesthetized animal was euthanatized for
staining of coronal brain sections with triphenyltetrazo-
lium chloride (TTC) [31]. Total percent infarct volume
was quantified using NIH Image v. 1.62 on a computer-
assisted imaging system described in our previous work
[26,29]. Infarct volume was corrected for ischemic edema
by the method of Swanson and co-authors [32].
For measurement of infarct volume after 7 days of post-
ischemic reperfusion, animals were re-anesthetized by IP
injection of chloral hydrate/xylazine and perfused tran-
scardially with 30 ml of cold, heparinized 0.1 M PBS (pH
7.4), followed by 60 ml of 4% paraformaldehyde in PBS.
Each brain was removed en bloc and placed in 4% parafor-
maldehyde/0.1 M PBS at 4°C for 24 hours. The fixed brain
specimen was then washed externally with PBS × 3 (10
minutes each) at 4°C. The brain specimen was blocked
and immersed in 20% sucrose/0.1 M PBS at 4°C for 24
hours. The fixed, sucrose-protected brain was mounted on
a metal chuck with cryostat embedding medium. The
mounted brain was frozen in powdered dry ice and
brought to ambient temperature within the cryostat (-
21°C) before 80-μm coronal sections were cut to encom-
pass the anticipated infarct volume. Every fifth section was
mounted directly onto glass microscopic slides that were
dried on a slide warmer at 40°C. The dried sections were
defatted in xylene overnight before rehydration through
gradient alcohol solutions to water. The resulting sections
were then stained in 5% cresyl violet acetate for 2 minutes,
rinsed in water, dehydrated through gradient alcohol
solutions to xylene, and coverslipped. Total percent inf-
arct volume was quantified using NIH Image v. 1.62 on
the same computer-assisted imaging system used for
quantifying 24-hour infarct volume, but without correc-
tion for tissue edema.
Assessment of neural cell death after focal cerebral 
ischemia
We employed both qualitative and quantitative methods
to evaluate apoptotic cell death in the brains of TNFα-
transgenic and non-Tg rats after ischemic injury. For qual-
itative determination of what cell type was undergoing
caspase-3 activation after ischemia, we adapted the
method of McEwen and Springer [33] from its original
application in experimental spinal cord trauma to our
model of suture-occlusion of the MCA. Twenty-four hours
after reversal of ischemia by withdrawal of the suture-
occluder, each rat was re-anesthetized by IP injection of
chloral hydrate/xylazine and perfused transcardially with
20 ml of cold, heparinized 0.1 M PBS (pH 7.4), followed
by 40 ml of 4% paraformaldehyde in PBS. The brain was
removed en bloc and placed in 4% paraformaldehyde in
PBS at 4°C for one hour. The fixed brain specimen was
then washed externally with PBS × 3 (10 minutes each) at
4°C. The brain specimen was then blocked and immersed
in 20% sucrose-PBS at 4°C for 48 hours, before being fro-
zen rapidly on dry ice and embedded in tissue freezing
medium (Triangle Biomedical Sciences, Durham, NC).
The frozen brain was then cut into 20-μm coronal sections
on a cryostat (Microm Laborgerate, Walldorf, Germany).
Consecutive sections taken from both TNFα-Tg and non-
Tg rats were mounted in pairs on a series of charged glass
slides (Superfrost Plus; Fisher Scientific, Pittsburgh, PA).
The sections were air-dried and stored at -20°C before
preparation for fluorescence immunohistochemistry, all
procedures for which were performed at room tempera-
ture except as noted. All sections were air-dried for 30
minutes after removal from cold storage, washed repeat-
edly in PBS for one hour, and pre-incubated for 30 min-
utes in a blocking solution comprised of 5% normal goat
serum (NGS) and 0.05% Triton X-100 in PBS. The block-
ing solution was removed and sections were incubated in
a humidified chamber overnight at 4°C in PBS that con-
tained 5% NGS and one of the following sets of primary
antibodies: (a) rabbit anti-human/mouse activated cas-
pase-3 IgG (polyclonal, 1:1,000; R & D Systems, Minneap-
olis, MN), (b) mouse anti-neuronal nuclei (NeuN) IgG
(monoclonal, 1:600; Chemicon International, Temecula,
CA) to identify neurons, or (c) anti-glial fibrillary acidic
protein (GFAP; monoclonal, 1:600; Sigma, St. Louis, MO)
to localize astrocytes. To test for nonspecific staining by
the secondary antibodies, additional slides were proc-
essed in a similar fashion with the primary antibodies
excluded. All slides were then washed repeatedly in PBS
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for one hour before being incubated in the dark for a sec-
ond hour in PBS that contained 5% NGS and the follow-
ing fluorescent secondary antibodies: Cy-3-conjugated
goat anti-rabbit IgG (polyclonal, 1:1,600; Jackson Immu-
noResearch Laboratories, West Grove, PA) and AlexaFluor
488 goat anti-mouse IgG (monoclonal, 1:600; Molecular
Probes, Eugene, OR). The secondary antibody solution
was removed and the slides were washed repeatedly in
PBS for 10 minutes. Tissue sections were immediately cov-
erslipped with ProLong Anti-Fade (Molecular Probes) and
stored in the dark at 4°C to retard fading of the fluores-
cent labels. A Zeiss AxioPlan microscope (Zeiss; Oberko-
chen, Germany) was used to review the tissue sections
after processing. Co-localization of immunoreactivity was
performed with Photoshop (Adobe Systems; San Jose,
CA) to superimpose paired images (40×) showing the flu-
orescent secondary antibodies identifying anti-active cas-
pase-3 and the cell type of interest.
To determine if neural cell death was preceded by caspase-
3 activation, we quantified the activity of this pro-apop-
totic enzyme in ischemic brain. TNFα-Tg and non-Tg rats
underwent MCAO by suture-occlusion for one hour. After
3 or 24 hours of post-ischemic reperfusion, each animal
was re-anesthetized by IP injection of chloral hydrate and
was perfused transcardially with 30 ml of 15% India ink
(v/v) diluted in normal saline, as per our published
method [27]. The brain was removed en bloc, chilled, and
cut into 2-mm sections. Normally perfused brain was
darkened by the ink, whereas unreperfused tissue
remained pale. The infarct core within each slice was dis-
sected and snap-frozen, as was a thin rim of partially
stained tissue at the interface between normal and
unreperfused cortex that approximated the ischemic
penumbra. The resulting tissue samples were prepared by
the micro-sample method described above and caspase-3
activity was measured with a caspase-3 substrate AC-
DEVD-AFC Fluorometric Assay Kit (R & D Systems). All
procedures were carried out according to the manufac-
turer's instructions. Equal amounts of protein samples
were mixed with caspase-3 reaction buffer containing the
fluorescent peptide AC-DEVD-AFC, pipetted in duplicate
in a 96-well microtiter plate, and incubated at 37°C for
180 minutes. Caspase-3 mediated cleavage of AC-DECD-
AFC into free AFC was measured using a fluorescent micro
plate reader (LS50B, Perkin Elmer) at a wavelength excita-
tion of 400 nm and emission of 505 nm. Readings were
obtained serially at 0, 30, 60, 120, and 180 minutes. The
change in fluorescence (Δ fluorescence units) was calcu-
lated by subtracting the minimal (t = 0 minutes) from the
maximal (t = 180 minutes) reading and the caspase-3
activity in each sample was calculated in Δ fluorescence
units/minute/100 mg protein.
To confirm that intracellular caspase-3 activation pre-
ceded apoptotic cell death, we performed a quantitative
assay for DNA fragmentation after focal cerebral ischemia.
For this technique, we adapted the method of Shimizu
and colleagues for measurement of DNA fragmentation in
ischemic gerbil hippocampus [34]. TNFα-Tg and non-Tg
rats underwent MCAO by suture-occlusion for one hour.
After 3 or 24 hours of post-ischemic reperfusion, each ani-
mal was re-anesthetized by IP injection of chloral hydrate
and was perfused transcardially with India ink. The brain
was removed en bloc, chilled, cut into 2-mm sections, and
sampled as described in the preceding paragraph. Frozen
tissue samples were homogenized with a glass tissue
grinder in isolation buffer comprised of 215 mM manni-
tol, 75 mM sucrose, 0.1% BSA, 1 mM EGTA (pH 7.2), and
20 mM HEPES (pH:7.2). Each homogenate was then cen-
trifuged at 3,000 × g for 5 min at 4°C to remove whole
DNA within intact cellular nuclei. The resulting superna-
tant was recentrifuged at 13,000 × g for 10 min at 4°C to
discard a crude mitochondrial pellet. The second superna-
tant enriched for cytosolic, fragmented DNA was aliquot-
ted and stored at -80°C. Protein concentration in the
second supernatant was measured with the BCA protein
assay kit (Pierce).
DNA fragmentation in the cytoplasmic supernatant was
quantitatively assayed by antibody-mediated capture and
detection of histone-associated DNA fragments (mono- or
oligonucleosomes; Cell Death Detection ELISA Plus kit;
Roche Molecular Biochemicals, Mannheim, Germany).
Briefly, a 20-μl aliquot of the cytoplasmic supernatant was
used in the ELISA following the manufacturer's standard
protocol. Optical density values of absorbance at 405 and
490 nm (reference wavelength) were determined with a
microplate reader (SpectraMAX 340PC, Molecular
Device) after incubation with a peroxidase substrate.
Background values (incubation buffer alone) were sub-
tracted from each sample. All samples were run in dupli-
cate. The direct reading units of OD values were converted
to mU (absorbance = 1000 mU). The results were shown
as mU (arbitrary unit) per mg protein.
Measurement of regional cerebral perfusion and 
quantification of vascular density
We used laser-Doppler flowmetry (LDF) to measure
regional cerebral perfusion in TNFα-Tg rats or non-Tg
controls during focal cerebral ischemia and post-ischemic
reperfusion. Following our previously reported method
[29], each animal underwent craniotomy for placement of
a 2-mm laser-Doppler probe over intact dura approxi-
mately 3 – 5 mm posterior to bregma and 4 mm lateral to
midline. The probe was positioned over a cortical region
affected by MCAO, from 4.2 mm anterior to 5.8 mm pos-
terior in relation to bregma, avoiding large pial vessels to
obtain reproducible, stable readings [35]. Baseline meas-
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urements were taken every five minutes during 10 min-
utes of pre-ischemic baseline, 60 minutes of MCAO, and
the first 30 minutes of post-ischemic reperfusion. Results
were expressed as percent of pre-ischemic baseline.
For quantification of vascular density, we employed a ster-
eological method used previously to study vascular
changes in rodent hippocampal dentate gyrus [36]. Male
TNFα-Tg and non-Tg rats (n = 3 per group) that were not
subjected to MCAO were anesthetized by IP injection of
sodium pentobarbital (55 mg/kg) and underwent thora-
cotomy to gain access to the heart. After cross-clamping of
the descending aorta, each animal was infused with 20 ml
undiluted Higgins black waterproof India ink #4115 (San-
ford, Bellwood, IL). The infusate was delivered through a
20-gauge needle inserted directly into the beating left ven-
tricle, using hand-applied pressure. The infused animal
was decapitated; the brain was then removed en bloc and
post-fixed in 4% paraformaldehyde for 48 hours. It was
then cryoprotected in 20% sucrose (w/v) for three days
under constant, mild agitation. Coronal sections of 50-
μm thickness were cut with a freezing microtome
throughout the rostral-caudal extent of a specified region
of the cortex extending from the septal area (inter-aural
level 10. 7) to the occipital region (inter-aural level -0.3)
[37]. The Bioquant Image Analysis System (Nashville, TN)
was used to analyze 12 equidistant sections taken from
every animal. For each section, an unbiased method [38]
was employed to select a region of interest (ROI; 5.26
mm2) within the cortex. With the Bioquant device, a
thresholding routine was used to estimate the percent area
of the ROI occupied by ink-labeled blood vessels. The vas-
cular percent areas within the ROIs in the 12 coronal sec-
tions were averaged to derive a mean value for each
animal.
Statistical analysis
All physiological measurements, levels of TNFα mRNA
and protein in brain, and infarct volumes by experimental
group were expressed as means ± SD. Unpaired t tests were
used for comparisons of group means for infarct volume,
cortical vascular density, and selected physiological meas-
urements (pre-ischemic whole blood glucose and hemat-
ocrit). All other physiological data, including
measurements of cortical perfusion by LDF, were
obtained serially in each rat and were compared by two-
way (experimental group and sampling time) analysis of
variance (ANOVA) with repeated measures. For compari-
son of TNFα mRNA or protein in different brain regions,
external organs, and serum in TNFα-Tg and non-Tg ani-
mals, ANOVA was used with Fisher's protected least sig-
nificant difference post hoc test that corrects for multiple
comparisons. TRADD protein levels and mouse/rat TNFα
mRNA ratios were also compared with ANOVA/Fisher's
test. Statistical significance was considered at p ≤ 0.05.
Results
Production and characterization of the TNFα-Tg rat
The murine TNFα promoter and the entire coding region
of the corresponding murine TNFα gene (Figure 1, Panel
a) were introduced into the TNFα-Tg rat. Weanling pups
underwent tail snip on post-natal Day 21 to obtain tissue
for isolation of total cellular DNA. The 501-kb fragment of
the murine TNFα gene was present only in the transgenic
animal, allowing confirmation of genotype by PCR (Fig-
ure 1, Panel b).
Cells that were immunoreactive for TNFα were found
only in the brain of the TNFα-Tg rat. By histological exam-
ination, the neural anatomy of the TNFα-Tg rat appeared
similar to that of non-Tg littermates (Figure 2, Panels a –
j) when not subjected to ischemic injury. Co-localization
Structure of the murine TNFα transgenic construct and con-firma ion f genotypeFigure 1
Structure of the murine TNFα transgenic construct 
and confirmation of genotype. The structure of the 
murine TNFα transgenic construct is illustrated in Panel a. 
An example of polymerase chain reaction (PCR) products 
stained with ethidium bromide to confirm the genotype of 
the TNFα-transgenic (TNFα-Tg) rat is shown in Panel b. 
Clear boxes in the drawing of the transgenic construct rep-
resent untranslated sequences from the mouse TNFα gene, 
black boxes indicate the coding region of the TNFα gene, 
and the gray box (including the remainder of the EcoRI to SalI 
fragment) represent the human β-globin 3' fragment. BS indi-
cates pBluescript vector. Panel b shows PCR products in tail 
snip tissue taken from a TNFα-Tg rat (Lane a), a non-trans-
genic littermate (Lane b), and a Sprague-Dawley rat (Lane c). 
A 501 bp fragment of the murine TNFα gene was detected 
only in the transgenic rat.
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studies (Figure 3, Panels a – c) showed overlap of signal
between mouse TNFα protein and a neuronal marker,
NeuN. This result identifying the rat neuron as the pri-
mary neural cell expressing TNFα protein was confirmed
in three TNFα-Tg rats from three different litters. Every
fifth coronal section was sampled in each of the three
transgenic animal brains.
Murine TNFα mRNA and protein were overepressed
abundantly in the TNFα-Tg rat. In Figure 4, multiple pan-
els show the results of assays for TNFα mRNA and protein
in transgenic animals and non-Tg littermates that were
not subjected to ischemic injury. The aggregate level of rat
and mouse TNFα mRNA assayed by RT-PCR (Panel a) was
fourfold higher in TNFα-Tg than in non-Tg rats (n = 3 per
animal type; p ≤ 0.01; unpaired t test). The mean level of
rat TNFα mRNA in the cortex of the transgenic rat, 1.3 ±
0.5 attomoles/μg total RNA, was not significantly different
from 0.8 ± 0.1 in the non-Tg animal and was no more
remarkable in cerebellum and brainstem (data not
shown). The aggregate level of rat and mouse TNFα pro-
tein in whole brain homogenate (Panel b) was fivefold
higher in TNFα-Tg rats (n = 3 per animal type; p ≤ 0.01;
unpaired t test). In Panel c, we show the results of a sec-
ond ELISA assaying for rat and mouse TNFα protein in
three brain regions (cortex, cerebellum, and brainstem), a
variety of organs outside the brain, and in randomly sam-
pled serum in both TNFα-Tg and non-Tg animals (n = 3
per animal type). Cortex and brainstem in the TNFα-Tg rat
had significantly higher levels (p ≤ 0.001; ANOVA/Fisher's
test). The level of aggregate TNFα protein in the cerebel-
lum of the TNFα-Tg animal (44 ± 18 pg/100 μg protein)
was higher than in the non-Tg rat (7 ± 3) but did not reach
statistical significance. It is noteworthy that the levels of
aggregate TNFα were almost two-fold higher in the heart,
kidney, and skeletal muscle of the transgenic animal in
comparison to non-Tg rats, although these differences
failed to reach statistical significance. We attributed the
difference in quantity of aggregate TNFα protein shown in
Panels b and c to the dilutional signal-to-noise loss in the
brain homogenate.
Focal cerebral ischemia in the TNFα-Tg rat
We induced focal cerebral ischemia by unilateral MCA
suture-occlusion in TNFα-Tg rats and non-Tg littermates.
Infarct volumes were calculated after 24 hours or 7 days of
post-ischemic reperfusion. The 24-hour infarct volumes
were derived by computer-assisted planimetry of digi-
tized, TTC-stained coronal brain slices; all data sets were
Figure 2
Cellular expression of TNFα protein in transgenic and non-transgenic rat braiFigur  2
Cellular expression of TNFα protein in transgenic 
and non-transgenic rat brain. This photographic collage 
shows cellular expression of TNFα protein and compares 
the brain anatomy of transgenic and non-transgenic (non-Tg) 
rats that were not subjected to ischemic injury. Coronal 
brain sections were incubated with primary antibodies identi-
fying mouse or rat TNFα protein (Panels a and b), neurons 
(Panels c and d), astroglia (Panels e and f), microglia/macro-
phages (Panels g and h), or oligodendroglia (Panels i and j). All 
light microscopic images were taken at 20× magnification. 
Transgenic rat brain is shown in Panels b, d, f, h, and j. All 
remaining images are of brain in non-Tg littermates. Cells 
that were immunoreactive for TNFα appeared only in trans-
genic animals, as shown in Panel b. A hash mark drawn to the 
left of each pair of 20× images represents the interface 
between neocortex and internal capsule. Scale bar = 100 μm
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corrected for edematous tissue expansion. The 7-day inf-
arct volumes were obtained by the same approach but
were derived from examination of coronal brain sections
stained with cresyl violet to identify Nissl substance. After
24 hours, TNFα-Tg rats had larger infarctions demon-
strated by TTC staining of coronal brain slices (Figure 5,
Panels a and b). In the TNFα-Tg rat (n = 12), mean infarct
volume ± SD was larger than in non-Tg littermate controls
(n = 17; p ≤ 0.05; unpaired t test; see Figure 5, Panel c).
Table 1 shows all physiological data obtained on ran-
domly sampled animals subjected to MCAO and meas-
urement of infarct volume by TTC staining. There was no
significant group-by-time interaction on two-way ANOVA
of any variable. These results support our conclusion that
between-group differences in infarct volume could not be
attributed to unique susceptibility of the TNFα-Tg rat to
hypoxemia or hypercarbia during or after ischemia.
Recognizing that TNFα and other inflammatory cytokines
rise to peak levels in rat brain within 24 – 48 hours after
ischemic injury [39], we re-assessed infarct volume 7 days
after reversal of MCAO to observe for a delayed effect on
injury progression. We also wished to know if the differ-
ence between infarct volumes in TNFα-Tg and non-Tg rats
observed at 24 hours proved resilient at 7 days. We found
that TNFα-Tg rats had larger infarcts that persisted after 7
days of post-ischemic reperfusion (Figure 6, Panels a and
b). Mean percent infarct volume remained higher in
TNFα-Tg rats (n = 10) than in non-Tg littermates (n = 11;
p ≤ 0.01; unpaired t test; see Figure 6, Panel c). We per-
formed between-group comparisons of mean pre-
ischemic body weight, anticipating that TNFα-Tg rats may
be affected by somatic wasting that could contribute to the
observed difference in infarct volume at 7 days. The pre-
ischemic mean weight in TNFα-Tg rats prepared for
MCAO and measurement of infarct volume at 7 days was
287.2 ± 33.5 (SD) g, compared to 310.1 ± 21 in non-Tg lit-
termates (p = NS).
To determine if ischemic stress altered the capacity for
constitutive synthesis of TNFα protein in the brain of the
transgenic animal, we examined regional levels of TNFα
protein and mRNA in TNFα-Tg and non-Tg rat brain after
3 or 24 hours of post-ischemic reperfusion. Figure 7 is a
composite bar graph showing mean levels of TNFα pro-Figure 3
Identification of neural cell type containing TNFα proteinFigure 3
Identification of neural cell type containing TNFα 
protein. This photographic collage shows the result of co-
localization studies identifying the neural cell type containing 
TNFα protein in the brain of the transgenic animal. All 
images were taken of TNFα-transgenic rat brain that had not 
been subjected to ischemic injury. Coronal brain sections 
were incubated with primary antibodies identifying mouse or 
rat TNFα protein and neurons. All images were made by flu-
orescence microscopy at 40× magnification. In Panel a, corti-
cal neurons in TNFα-Tg rat brain are immuno-labeled with 
the anti-neuronal antibody NeuN tagged with a green fluoro-
phore. In Panel b, co-localization images are merged to show 
that several NeuN-labeled neurons (green) express TNFα 
protein immuno-labeled with anti-mouse/rat TNFα antibody 
tagged with a red fluorophore. In Panel c, co-localization 
images are merged to show NeuN-labeled neurons (green), 
TNFα protein (red), and cellular nuclei labeled with Hoechst 
stain (blue). A representative neuron with cytoplasmic inclu-
sions labeled to show expression of TNFα protein is identi-
fied in each Panel (arrow). In Panel c, nuclei of several non-
neuronal cells that do not express TNFα protein are shown. 
Scale bar = 50 μm
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tein (Panel a) and the corresponding mean ratios of
mouse to rat TNFα mRNA (Panel b) in the border zone
approximating the ischemic penumbra and in the devel-
oping infarct core of both TNFα-Tg and non-Tg rats. The
results in Panel a confirm that TNFα protein in control tis-
sue from the transgenic rat is present in almost twice the
quantity found in non-Tg littermates, as would be
expected from assay of TNFα in non-ischemic brain tissue
obtained from both animals shown in Figure 3. After 3
hours of reperfusion in animals subjected to MCAO,
mean TNFα levels within the border zone and the devel-
oping infarct core in the TNFα-Tg rat rose above those in
the non-Tg animal by statistically insignificant margins.
However, mean TNFα levels became significantly elevated
within the border zone and infarct core after 24 hours of
reperfusion in both TNFα-Tg and non-Tg rats, in compar-
ison to animals of the respective type whether non-
ischemic controls or ischemic rats 3 hours after reversal of
MCAO (n = 3 – 4 per group; p ≤ 0.001 for all pairwise
comparisons; ANOVA/Fisher's test). In addition, the
mean TNFα level in the border zone adjacent to the infarct
core in the TNFα-Tg rat at 24 hours was significantly
Organ-specific expression of TNFα mRNA and protein in transgenic and non-transgenic ratsFigure 4
Organ-specific expression of TNFα mRNA and protein in transgenic and non-transgenic rats. Two bar graphs 
show aggregate rat and mouse TNFα mRNA (Panel a) or protein (Panel b) in brain homogenates prepared from transgenic ani-
mals and non-transgenic (non-Tg) littermates (n = 3 in each group). A third bar graph (Panel c) shows TNFα protein levels in 
three brain compartments, various external organs, and randomly obtained serum samples from a second set of transgenic and 
non-Tg animals (n = 3 in each group). No animal was subjected to ischemic brain injury. In Panel a, the mean ± SD level of 
TNFα mRNA was significantly higher in transgenic rats (p ≤ 0.01; unpaired t test). The mean TNFα protein level was also sig-
nificantly elevated in transgenic animals, as shown in Panel b (p ≤ 0.01; unpaired t test). When TNFα protein was surveyed in 
multiple organs and in serum, its content in cortex and brainstem was at least fivefold higher than in non-Tg animals (p ≤ 0.001; 
ANOVA/Fisher's test). **p ≤ 0.01; ***p ≤ 0.001
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higher than the comparable level in the non-Tg animal (p
≤ 0.01; ANOVA/Fisher's test). Mean ratios of mouse and
rat mRNA trended upward in all brain regions and at both
sampling times in TNFα-Tg rats, compared to non-Tg lit-
termates. However, this trend achieved statistical signifi-
cance only between control animals that were not
subjected to ischemic injury (p ≤ 0.01; ANOVA/Fisher's
test).
To confirm that TNFα protein synthesized in the brain of
the transgenic animal is biologically active, we quantified
expression of TRADD protein. Homogenates of brain
sampled from TNFα-Tg and non-Tg rats were incubated
with a primary antibody that recognizes rat TRADD only
after it has been activated through binding of TNFα to
p55/TNFR1, thereby implying biological activity of the
cytokine. Regional expression of TRADD protein was uni-
formly higher in TNFα-Tg rat brain than in non-Tg con-
trols by statistically significant margins (see Figure 8).
After 3 hours of post-ischemic reperfusion, mean TRADD
expression in TNFα-Tg brain was increased in the infarct
core (n = 5 per animal type; p ≤ 0.05; ANOVA/Fisher's
test) and in the adjacent border zone approximating the
ischemic penumbra (p ≤ 0.01; ANOVA/Fisher's test). To
demonstrate that chronically elevated levels of TNFα
enhanced expression of TRADD protein without ischemic
stress, we sampled cortical tissue from the normally-per-
fused hemisphere in ischemic animals and found that
TRADD was nearly threefold higher in the TNFα-Tg rat (p
≤ 0.01 compared to non-Tg animals; ANOVA/Fisher's
test). There were no significant differences between
TRADD protein expression in the normally-perfused hem-
isphere and the ischemic border zone or infarct core in the
TNFα-Tg rat (p = NS).
Apoptotic cell death after focal cerebral ischemia in the 
TNFα-Tg rat
We performed a qualitative assessment of apoptotic cell
death, supported by quantitative assays of caspase-3 acti-
vation and DNA fragmentation in the ischemic brain of
the TNFα-Tg and non-Tg rat. In Figure 9, co-localization
studies in normal or ischemic striatum taken from trans-
genic and non-Tg animals prove that neurons show cyto-
plasmic caspase-3 activation while undergoing apoptotic
death 24 hours after MCAO. Parallel studies performed to
determine if caspase-3 activation was also observed in
astroglia showed only rare astrocytes with co-localized
GFAP and caspase-3 activation in ischemic striatum of
both animals (data not shown). Comparison of Panel d to
b in Figure 9 suggests, but does not prove, that degenerat-
ing neurons showing caspase-3 activation are more abun-
dant in ischemic striatum within transgenic than in non-
Tg brain. Apoptotic bodies were observed within degener-
ating neurons in ischemic TNFα-Tg rat brain (see Figure
10).
To pursue this observation implying that the TNFα-Tg rat
may be susceptible to apoptotic neuronal death, we meas-
ured caspase-3 activity in the infarct core and in the border
zone region approximating the ischemic penumbra in
























TNFα-Transgenic Rats (n = 7)
Pre-ischemic 
Sample
4.29 ± 0.38 47 ± 1 36 ± 0.4/36 ± 0.4 99 ± 10 73 ± 6 47 ± 4 7.30 ± 0.02
Ischemic Sample - - 37 ± 0.2/37 ± 0.3 84 ± 13 71 ± 5 44 ± 4 7.30 ± 0.02
Post-ischemic 
Sample
- - 37 ± 0.3/37 ± 0.5 84 ± 9 70 ± 3 43 ± 4 7.31 ± 0.02
Non-Transgenic Controls (n = 12)
Pre-ischemic 
Sample
4.18 ± 0.80 47 ± 2 36 ± 0.6/36 ± 0.5 96 ± 13 71 ± 8 50 ± 3 7.29 ± 0.02
Ischemic Sample - - 37 ± 0.3/36 ± 0.3 92 ± 12 69 ± 8 48 ± 3 7.29 ± 0.02
Post-ischemic 
Sample
- - 37 ± 0.4/37 ± 0.4 88 ± 14 71 ± 7 45 ± 3 7.30 ± 0.02
Arterial blood samples were obtained 15 minutes before insertion of the suture (pre-ischemic sample), immediately before its removal (ischemic 
sample), and after 15 minutes of reperfusion (post-ischemic sample).
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both animals. In the TNFα-Tg rat, caspase-3 activity was
significantly greater than in non-Tg controls within the
border zone and in the developing infarct after 3 hours of
reperfusion (see Figure 11; n = 3 – 4 per group; p ≤ 0.05
for all pairwise comparisons; ANOVA/Fisher's test). At 24
hours, caspase-3 activity remained significantly higher
within the infarct core of the TNFα-Tg rat compared to
controls (p ≤ 0.05; ANOVA/Fisher's test). As a direct,
quantitative measure of apoptotic cell death in ischemic
brain, we assayed DNA fragmentation represented by his-
tone-associated DNA complexes released into cellular
cytoplasm. In the border zone approximating the
Quantification of brain infarct volume in TNFα-transgenic and non-transgenic rats at 24 hoursFigure 5
Quantification of brain infarct volume in TNFα-transgenic and non-transgenic rats at 24 hours. Representative 
infarcts are shown in the brain of a non-transgenic (Panel a) and a TNFα-transgenic (TNFα-Tg) rat (Panel b). In Panel c, a bar 
graph shows mean percent infarct volume in both TNFα-Tg and non-Tg rats. All animals underwent suture-occlusion of the 
right middle cerebral artery for one hour followed by 24 hours of post-ischemic reperfusion. The 1-mm coronal brain sections 
in Panels a and b were stained for triphenyltetrazolium chloride. Panel a shows infarction (blanched tissue) confined to the right 
cortical mantle and a portion of the underlying striatum in a non-Tg rat. In the transgenic animal shown in Panel b, there is 
blanching of tissue in the right cortical mantle that indicates completed infarction and mottled discoloration throughout the 
entire ipsilateral striatum that is a maturing infarct. Panel c shows that mean ± SD infarct volume in the transgenic group (n = 
12) was significantly greater than that of the non-Tg group (n = 17; *p ≤ 0.05; unpaired t test). All volume measurements were 
corrected for tissue edema.
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ischemic penumbra in TNFα-Tg rat brain sampled at 24
hours, mean DNA fragmentation was increased by almost
200-fold compared to non-ischemic transgenic brain (see
Figure 12; p ≤ 0.0001), over 60-fold compared to border
zone tissue in ischemic TNFα-Tg brain sampled at 3 hours
(p ≤ 0.001), and by 4-fold over that observed in non-Tg
brain after 24 hours of post-ischemic reperfusion (p ≤
0.01; n = 6 – 7 per group; all between-group comparisons
by ANOVA/Fisher's test). Within the developing infarct
core, DNA fragmentation was again increased by almost
200-fold compared to the non-ischemic transgenic brain
(p ≤ 0.0001) and 60-fold compared to infarct zone tissue
sampled from TNFα-Tg rat brain at 3 hours (p ≤ 0.001; all
between-group comparisons by ANOVA/Fisher's test).
There was no significant between-group difference in ele-
vated mean levels of DNA fragmentation within the inf-
arct core after 24 hours of post-ischemic reperfusion (p =
NS). These quantitative results corroborate the findings of
Quantification of brain infarct volume in TNFα-transgenic and non-transgenic rats at 7 daysFigure 6
Quantification of brain infarct volume in TNFα-transgenic and non-transgenic rats at 7 days. Representative inf-
arcts are shown in the brain of a non-transgenic (non-Tg; Panel a) and a TNFα-transgenic (TNFα-Tg) rat (Panel b). In Panel c, a 
bar graph shows mean ± SD infarct volume in both TNFα-Tg and non-Tg rats. All animals underwent suture-occlusion of the 
right middle cerebral artery for one hour followed by 7 days of post-ischemic reperfusion. The 80-μm coronal sections of brain 
shown in Panels a and b were stained with cresyl violet for Nissl substance. Panel a shows well-demarcated infarction confined 
to the right cortical mantle and a portion of the underlying striatum in the non-Tg rat. In the transgenic animal shown in Panel 
b, the infarct occupies a larger proportion of the right cortical mantle and almost all of the ipsilateral striatum. Panel c shows 
that mean infarct volume in the transgenic group (n = 10) was significantly greater than that of the non-Tg group (n = 11; **p ≤ 
0.01; unpaired t test).
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the co-localization studies in Figures 9 and 10 showing
that the TNFα-transgenic rat is highly susceptible to apop-
totic neuronal death after ischemia.
Cerebral blood flow in the TNFα-Tg rat
After observing larger infarct volumes in the TNFα-Tg rat
after 24 hours and 7 days of post-ischemic reperfusion, we
were obligated to determine if the apparent susceptibility
of the transgenic animal to ischemic injury was related to
genetic modification of cerebral vascular reactivity or den-
sity. We used laser-Doppler flowmetry for serial measure-
ment of cortical perfusion before, during, and
immediately after MCAO to assess cerebral vascular reac-
tivity in TNFα-Tg rats and non-Tg littermates. The multi-
line plot in Figure 13 demonstrates that cortical perfusion
within the infarct core of the TNFα-Tg rat fell below that
of non-Tg controls shortly after MCAO. The TNFα-Tg rats
had significantly lower mean LDF at 5 and 10 minutes of
ischemia (n = 19 – 21 per animal type; p ≤ 0.01 and p ≤
0.05, respectively; repeated measures ANOVA). There
were no significant differences in LDF between the two
groups of animals during the remaining 50 minutes of
ischemia or 30 minutes of post-ischemic reperfusion.
Stereological analysis of vascular structures in the cortex
showed that there was no change in micro-vascular anat-
omy caused by expression of the transgenic construct in
the brain of the TNFα-Tg rat. The mean percent cortical
area occupied by vascular structures in the cerebral cortex
of the TNFα-Tg rats not subjected to MCAO was 6.20 ±
0.20, compared to 6.57 ± 0.31 in non-Tg littermates (p =
NS). Figure 14 shows representative photomicrographs of
micro-vascular structures within the cerebral cortex in
both animal types.
Discussion
This work confirms that the TNFα-Tg rat survives to adult-
hood, reproduces effectively, demonstrates upregulated
expression of TNFα mRNA and protein in brain, and is
susceptible to infarction by MCAO. Our results show that
the high level of TNFα mRNA expressed constitutively in
the brain of the transgenic animal is derived almost com-
pletely from the murine construct and not from the native
rat gene. TNFα protein is increased selectively in the brain
and by a statistically insignificant margin in the heart, kid-
ney, and skeletal muscle, but remains low in serum and
other external organs. TNFα-immunoreactive cells of neu-
ronal morphology are present only in the neocortex of the
transgenic animal. The distribution of the various cell
Figure 7
Regional expression of TNFα mRNA and protein in brain after focal ischemiaFigure 7
Regional expression of TNFα mRNA and protein in 
brain after focal ischemia. Two bar graphs show mean ± 
SD levels of TNFα protein (Panel a) and the corresponding 
mean ratios of mouse to rat TNFα mRNA (Panel b) in trans-
genic and non-transgenic rat brain with or without ischemic 
brain injury. TNFα-transgenic (TNFα-Tg) and non-Tg rats 
underwent one hour of focal brain ischemia achieved by uni-
lateral middle cerebral artery occlusion (MCAO). Tissue 
samples were obtained from the developing infarct core and 
the border zone approximating the ischemic penumbra in 
both groups of animals after 3 or 24 hours of post-ischemic 
reperfusion. As shown in Panel a, mean TNFα levels were 
significantly elevated within the border zone and infarct core 
after 24 hours of reperfusion in both TNFα-Tg and non-Tg 
rats, in comparison to animals of the respective type whether 
non-ischemic controls or ischemic rats sampled 3 hours after 
reversal of MCAO (n = 3 – 4 per group; p ≤ 0.001 for all 
pairwise comparisons; ANOVA/Fisher's test). The mean 
TNFα level in the border zone adjacent to the infarct core in 
the transgenic rat at 24 hours was significantly higher than 
the comparable level in the non-Tg animal (p ≤ 0.01; 
ANOVA/Fisher's test). Panel b of Figure 5 shows the mean 
ratios of mouse and rat TNFα mRNA corresponding to the 
TNFα protein levels from the same animals reported in Panel 
a. The mean ratio of mouse/rat TNFα mRNA was signifi-
cantly higher in TNFα-Tg rats compared to the non-Tg ani-
mals only under control conditions without ischemia (p ≤ 
0.01; ANOVA/Fisher's test). **p ≤ 0.01; ***p ≤ 0.001
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populations in the brain of the TNFα-Tg rat appears no
different than in the non-Tg animal, suggesting that the
transgene has no measurable effect on the structural
organization of the neocortex.
Our immunohistochemical studies indicate that the pre-
dominant cell type secreting TNFα in the brain of the
transgenic rat is of neuronal lineage. This observation of
constitutive neuronal expression differs importantly from
previous studies showing that TNFα is frequently undetec-
table in quiescent neural cell populations, becoming
upregulated in neurons and astroglial cells only after
ischemic or post-traumatic stress [40,41]. In a compre-
hensive study of the evolution of TNFα expression in the
brains of human patients with acute ischemic stroke,
Sairanen and colleagues [6] found that TNFα expression
appeared in neurons located within the infarct core and in
the adjacent border zone during 24 hours after the onset
of infarction. Reactive astrocytes then expressed TNFα
immunoreactivity in both the injured hemisphere and in
the contralateral hemisphere, beginning within 24 hours
of stroke and persisting for up to 18 days afterward. These
findings indicate that multiple neural cell types have the
capacity to express TNFα, thereby emphasizing that this
proinflammatory cytokine participates in an evolving
brain injury response culminating in delayed involvement
of "unaffected" tissue.
The suture-occlusion model of focal cerebral ischemia is
feasible in the TNFα-Tg rat and produces a larger mean
volume of infarction than in non-Tg littermates. We spec-
ulate that the greater infarct volume observed in the trans-
genic animal resulted from chronic overexpression of
TNFα protein within the brain, causing receptor-mediated
caspase activation that promoted neuronal apoptosis
[42]. Binding of active, soluble TNFα to p55/TNFR1 will
recruit TRADD, activate effector caspase-8, and cleave the
executioner caspase-3 for activation [43]. Our observation
that TRADD protein is expressed intensely within and out-
side of the ischemic focus in TNFα-Tg rat brain indicates
that the cytokine produced in this animal is biologically
active. We found significantly elevated levels of TNFα
within ischemic tissue in the brain of the TNFα-Tg rat after
24 hours of post-ischemic reperfusion, but without corre-
sponding increases in the component of mRNA tran-
scribed from the murine TNFα gene. We speculate that the
TNFα-Tg rat may have elevated TACE activity to facilitate
synthesis of TNFα from its inactive precursor, thereby
requiring no additional transcription of TNFα mRNA.
Overall, our results suggest that it is soluble TNFα, not its
membrane-bound precursor, which is active in the brain
of the transgenic animal. Furthermore, our present find-
ings allow us to conclude only that TNFα binds to p55/
TNFR1 in the TNFα-Tg rat.
Our supposition that the pivotal mediator of increased
lesion volume is the excess brain content of TNFα protein
in the transgenic rat is corroborated by the work of Barone
and colleagues [13]. To directly examine the role of early
TNFα production in the evolution of secondary ischemic
injury, these investigators administered exogenous TNFα
by intracerebroventricular (ICV) injection 24 hours before
MCAO to achieve permanent or transient focal ischemia
in rats. They found that motor function, hemispheric
edema, and infarct volume were affected adversely in a
dose-dependent manner by TNFα. Furthermore, the spe-
cificity of the effect of higher doses of TNFα to cause pro-
gressively larger infarcts was confirmed by reduction of
infarct volume after ICV injections of an anti-TNFα neu-
tralization antibody or of soluble TNFR1 before and after
Biological activity of TNFα in transgenic rat brain shown by TRADD prote n expressionF gure 8
Biological activity of TNFα in transgenic rat brain 
shown by TRADD protein expression. This bar graph 
shows expression of TNF receptor-associated protein death 
domain (TRADD) protein in brain homogenates obtained 
from TNFα-transgenic (TNFα-Tg) and non-Tg rats. Samples 
were obtained after 3 hours of reperfusion following one 
hour of focal cerebral ischemia. TRADD protein expression 
is shown as mean ± SD optical density units measured from 
digitized electrophoretic bands. In ischemic TNFα-Tg brain, 
TRADD protein was expressed more intensely within the 
border zone approximating the ischemic penumbra (n = 5 
per group; p ≤ 0.01; ANOVA/Fisher's test) and in the devel-
oping infarct core (p ≤ 0.05; ANOVA/Fisher's test) when 
compared to non-Tg littermates. TRADD was also elevated 
significantly in the normally-perfused hemisphere (control) of 
the TNFα-Tg rat compared to non-Tg animals (p ≤ 0.01; 
ANOVA/Fisher's test), reflecting increased constitutive 
expression of protein in response to interaction between 
active, soluble TNFα and its p55/TNFR1 receptor. There 
were no significant differences between TRADD protein 
expression in the normally-perfused hemisphere and the 
ischemic border zone or infarct core in TNFα-Tg rats (p = 
NS). *p ≤ 0.05; **p ≤ 0.01
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MCAO. This relationship between lesion volume and
ambient level of TNFα has been confirmed repeatedly in
animal models of focal cerebral ischemia [14,15,44,45]
and has even been observed in human stroke victims.
Montaner and co-workers [46] found positive correlations
between elevated blood levels of TNFα or interleukin-6
and the volume of hypoperfused brain observed after
bolus-tracking perfusion MRI studies in stroke patients.
We examined brain perfusion by LDF to determine if the
larger mean infarct volume in the TNFα-Tg rat was caused
by an unanticipated effect of the constitutively expressed
TNFα mRNA or translated protein on the cerebral circula-
tion. We found that cortical perfusion within the infarct
core in the brain of the TNFα-Tg rat fell to 20% of pre-
ischemic baseline within 5 minutes after MCAO. Beyond
the first 10 minutes of MCAO, there was no significant dif-
ference in cortical flow between transgenic and non-Tg
animals for the remaining 50 minutes of focal ischemia
Co-localization studies identifying neuronal apoptosis after focal cerebral ischemiaFigure 9
Co-localization studies identifying neuronal apoptosis after focal cerebral ischemia. A collage of 40× photomicro-
graphs shows localization of activated caspase-3 (red) in NeuN-positive striatal neurons (green) after focal cerebral ischemia in 
TNFα-transgenic (TNFα-Tg) and non-Tg rats. Panels a and c are representative images of striatum in the left cerebral hemi-
sphere of a non-Tg (a) and a TNFα-Tg (c) rat subjected to one hour of suture-occlusion of the right middle cerebral artery, fol-
lowed by 24 hours of reperfusion. Note the absence of activated caspase-3 in NeuN-positive striatal neurons of the cerebral 
hemisphere contralateral to the ischemic injury in both animals. Panels b and d are taken from the ischemic striatum in the 
same non-Tg (b) and TNFα-Tg (d) rats. The presence of activated caspase-3 is clearly evident in NeuN-positive striatal neu-
rons (arrows), many of which exhibit morphological changes consistent with ongoing cell death. Scale bar = 100 μm.
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and 30 minutes of post-ischemic reperfusion. This result
suggests that constitutive upregulation of TNFα protein
could accentuate brain response to focal circulatory arrest
and may have contributed to the larger mean percent inf-
arct volume observed in transgenic animals. However, the
transience of the effect on LDF in the ischemic TNFα-Tg
rat is self-evident and was not corroborated by underlying
changes in micro-vascular anatomy, as was shown in our
stereological analysis of cortical vascular density.
Our speculation of a link between elevated TNFα in brain
and cortical perfusion is corroborated by Lavine and col-
leagues [45] who found that pre-ischemic administration
of an anti-TNFα neutralization antibody one hour before
MCAO significantly improved perfusion in the infarct
core and in the peri-infarct region after reversal of MCAO
in non-Tg animals. Alternately, Savitz and others [47]
showed that pre-ischemic administration of carvedilol, a
mixed α and β adrenoreceptor antagonist, reduced TNFα
mRNA copy number, infarct volume, and ischemic apop-
tosis after MCAO but had no effect on LDF. Recent studies
suggest that TNFα may affect brain endothelial cell func-
tion or microvascular integrity, even if its influence on reg-
ulation of cerebral hemodynamic function after ischemia
remains ambivalent. Kimura and coworkers [48] reported
that TNFα induced cleavage of caspase-3 and promoted
apoptosis in cultured brain microvascular endothelial
cells. Hosomi and others [44] found that TNFα may
increase microvascular permeability after ischemia by
upregulating matrix metalloproteinases (MMPs). They
observed that intravenous infusion of an anti-TNFα neu-
tralization antibody immediately after reversal of MCAO
inhibited upregulation of MMP-9 and membrane type 1-
MMP, thereby lowering infarct volume and attenuating
ischemic brain edema.
We have confidence that the unique cellular anatomy and
the response to ischemic brain injury observed in our
transgenic animal cannot be attributed to random genetic
heterogeneity. Transgenic animals are often produced on
a hybrid background and then backcrossed to optimize
genetic homogeneity. The TNFα-Tg rats were produced on
the outbred S-D rat strain. All subsequent generations of
transgenic animals have been prepared by backcrossing
onto this same strain. We have used non-Tg littermates as
controls in all the assays we performed to quantify TNFα
mRNA and protein levels and verify cellular anatomy.
Co-localization study revealing apoptotic bodies within degenerating euron in ischemic TNFα-transg nic rat brainFi ur  10
Co-localization study revealing apoptotic bodies 
within degenerating neuron in ischemic TNFα-trans-
genic rat brain. A single 40× photomicrograph shows local-
ization of activated caspase-3 (red) in NeuN-positive cortical 
neurons (green) after focal cerebral ischemia in the TNFα-
transgenic (TNFα-Tg) rat. The right cerebral cortex was 
sampled after one hour of suture occlusion of the ipsilateral 
middle cerebral artery, followed by 24 hours of reperfusion. 
In the representative NeuN-positive neuron identified by the 
arrow, there is caspase-3 activation with apoptotic bodies 
identified by Hoechst staining (blue). Scale bar = 50 μm.
Caspase-3 activity in TNFα-transgenic and non-transgenic rat brain after focal ischemiaFigure 11
Caspase-3 activity in TNFα-transgenic and non-trans-
genic rat brain after focal ischemia. The bar graph 
shows caspase-3 activity in the brains of TNFα-transgenic 
(TNFα-Tg) and non-Tg rats (n = 3 – 4 per group and sam-
pling time) with or without ischemic brain injury. TNFα-
transgenic (TNFα-Tg) and non-Tg rats underwent one hour 
of focal brain ischemia achieved by unilateral middle cerebral 
artery occlusion. Tissue samples were obtained from the 
developing infarct core and the border zone approximating 
the ischemic penumbra in both groups of animals after 3 or 
24 hours of post-ischemic reperfusion. Caspase-3 activity is 
presented as Δ fluorescence units/minute/100 mg protein 
(mean ± SD). Transgenic animals had significantly greater cas-
pase-3 activity in the border zone region after 3 hours of 
reperfusion and in the infarct core at both 3 and 24 hours (p 
≤ 0.05; ANOVA/Fisher's test).*p ≤ 0.05 compared to respec-
tive control.
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TNFα-Tg animals express a uniform phenotype that dif-
fers consistently from the non-Tg littermates. Therefore,
we believe that the unique features of the TNFα-Tg rat
must be attributed to segregation of the transgene allele.
With its chronic upregulation of TNFα in brain, the TNFα-
Tg rat is a clinically relevant model of secondary inflam-
matory changes after cerebral infarction in humans.
Although non-Tg animals show increased levels of endog-
enous TNFα in response to ischemia, the transgenic rat
has greater research potential because of the ease with
which signal transduction and pro-apoptotic pathways
may be studied under conditions of prolonged activation
in vivo. Even though TNFα-Tg mice share this asset, their
role in the assessment of experimental therapeutic agents
will be limited by small size, restricted vascular access, and
constrained use in functional assessment of motor and
cognitive behavior. The TNFα-Tg rat is a valuable new tool
for the study of cytokine-mediated signal transduction
paths in ischemic brain injury.
Quantification of apoptotic cell death by DNA fragmentation >in TNFα-transgenic and non-transgenic rat brain after focalischemiaF gure 12
Quantification of apoptotic cell death by DNA frag-
mentation in TNFα-transgenic and non-transgenic 
rat brain after focal ischemia. The bar graph shows DNA 
fragmentation representing apoptotic cell death in brain sam-
pled from TNFα-transgenic (TNFα-Tg) and non-Tg rats (n = 
6 – 7 per group and sampling time) after one hour of unilat-
eral middle cerebral artery occlusion (MCAO). Tissue sam-
ples were obtained from the developing infarct core and the 
border zone approximating the ischemic penumbra in both 
groups of animals after 3 or 24 hours of post-ischemic reper-
fusion. Neural cell death represented by DNA fragmentation 
is presented as mU/mg protein (mean ± SE). Cell death rep-
resented by DNA fragmentation was present at only negligi-
ble levels in non-ischemic TNFα-Tg and non-Tg controls (n = 
12 per group) and after MCAO followed by 3 hours of post-
ischemic reperfusion (p = NS for all pairwise comparisons). 
However, DNA fragmentation increased markedly after 24 
hours of post-ischemic reperfusion in both TNFα-Tg and 
non-Tg rats. In the border zone approximating the ischemic 
penumbra in TNFα-Tg brain sampled at 24 hours, mean 
DNA fragmentation was increased by almost 200-fold com-
pared to the respective non-ischemic control (p ≤ 0.0001; 
ANOVA/Fisher's test) and over 60-fold compared to border 
zone tissue sampled from TNFα-Tg brain at 3 hours (p ≤ 
0.001; ANOVA/Fisher's test). DNA fragmentation in this 
region sampled from TNFα-Tg brain was almost 4-fold 
higher than that observed in non-Tg brain after 24 hours of 
post-ischemic reperfusion (p ≤ 0.01; ANOVA/Fisher's test). 
Within the infarct zone of TNFα-Tg brain sampled at 24 
hours, mean DNA fragmentation was again increased by 
almost 200-fold compared to the respective non-ischemic 
control (p ≤ 0.0001; ANOVA/Fisher's test) and 60-fold com-
pared to infarct zone tissue sampled from TNFα-Tg brain at 
3 hours (p ≤ 0.001; ANOVA/Fisher's test). There was no sig-
nificant difference observed between the elevated mean lev-
els of DNA fragmentation within the infarct zone in TNFα-
Tg and non-Tg rat brain after 24 hours of post-ischemic 
reperfusion (p = NS). **p ≤ 0.01; ***p ≤ 0.001; †p ≤ 0.0001
Measurement of cortical perfusion during focal cerebral ischemia in TNFα-t ansgenic and on-transgeni  ratsFigure 13
Measurement of cortical perfusion during focal cere-
bral ischemia in TNFα-transgenic and non-transgenic 
rats. The multi-line plot shows laser-Doppler flowmetry 
(LDF) measurements of cortical perfusion expressed as a 
percentage of pre-ischemic baseline in TNFα-transgenic 
(TNFα-Tg; n = 19) rats and non-Tg littermates (n = 21). 
Measurements were made every 5 minutes during 10 min-
utes of pre-ischemic baseline, 60 minutes of ischemia, and 30 
minutes of post-ischemic reperfusion. Values were calculated 
as a percentage of pre-ischemic baseline and are presented as 
means ± SD. The TNFα-Tg rats had significantly lower mean 
LDF at 5 and 10 minutes immediately after the onset of 
ischemia (P = 0.0016 and 0.034, respectively; repeated meas-
ures ANOVA). *p ≤ 0.05; **p ≤ 0.01
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